Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In

May 18 2020

• By Brenda Sandburg

Patent Health Care Pharmaceuticals Innovation concept. — Intellectual property is central to COVID-19 innovation and collaboration, Novartis exec says

Related Content

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Mar 26 2020

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Apr 07 2020

NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer

Apr 19 2020

Gilead Licensing Deal Expands Remdesivir Access, Capacity

May 13 2020

Gilead's Request To Revoke Remdesivir Orphan Designation Reflects Pandemic Pressures

Mar 26 2020

Related Companies

Novartis AG

Gilead Sciences, Inc.

Additional Topics

Coronavirus COVID-19 Intellectual Property Legal Issues Policy BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window